chartexchange

SK Biopharmaceuticals Submits Supplemental New Drug Application to U.S. FDA for Cenobamate

PR Newswire | Nov 4, 2026 9:52 AM EST

Application seeks indication for primary generalized tonic-clonic (PGTC) seizures and expansion of existing focal-onset seizure indication to pediatric patients - Submission supported by results from a global Phase 3 trial evaluating the efficacy and safety of cenobamate in patients with...

Read original article